🦊/Investors

BRV Capital ManagementFull Portfolio

6 tracked investments · listed companies and verified rows first

Arvelle Therapeuticsangelinipharma.chinFeb 2019 · $180M

Angelini Pharma Switzerland is the Swiss arm of a pharmaceutical company focused on brain health and epilepsy, offering prescription treatments for patients and healthcare professionals.

BiotechConsumerHealthtechZug, CH

Co-investorsAndera PartnersF-Prime CapitalH.I.G. CapitalH.I.G. HealthBridge PartnersH.I.G. BioHealth PartnersLife Sciences Partners

Spekter Gamesspekter.games𝕏Jun 2025 · $5M

Spekter Games develops and publishes Web2 games with passive Web3 reward layers on chat-based super apps such as Telegram and LINE, targeting mainstream gamers.

ConsumerCrypto & Web3Gaming

TK(Founder)

Co-investorsChamaeleonA16Z SpeedrunAccelerator VenturesAlumni VenturesImpact46London Venture Partners

Verismo Therapeuticsverismotherapeutics.comin

Verismo is a biopharmaceutical company founded by the inventors of Kymriah, the first FDA-approved CAR T cell therapy, developing next-generation CAR T therapies using KIR receptor technology to address limitations in first-generation approaches.

BiotechDeep TechHealthtechMedical DevicesPhiladelphia, US

Bryan Kim(Co-Founder and CEO/President)inGene Kim(Executive Officer)in

BoardJong Sun Yoon(Director)Dong Gun Kim(Director)Yang Gon Jin(Director)

Co-investorsBlueRun Ventures

Wrtnwrtn.ioMar 2025 · $18.3M

Wrtn Technologies (Wrtn) builds consumer and business-facing generative AI products, including Korea's first generative AI copywriting service and AI entertainment apps, and runs enterprise/government AI transformation projects.

AI & Machine LearningConsumerEnterprise Software

Youngjoon Yoo(Founder)in

Co-investorsAntlerKrew Capital VentureZ Venture CapitalDCM VenturesGoodwater CapitalKB Securities+1 more

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Key ProteoProteo

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.